Ad hoc: Biofrontera AG: Distribution Agreement with Spirit Healthcare Lim. for Ameluz® in UK and Ireland

Biofrontera AG / Ad hoc: Biofrontera AG: Distribution Agreement with Spirit Healthcare Lim. for Ameluz® in UK and Ireland . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Leverkusen, 24 July 2012 - Biofrontera Pharma GmbH, a fully-owned subsidiary of Biofrontera AG, has today signed an exclusive agreement with Spirit Healthcare Limited, Leicester, England, for the marketing of Ameluz(®) in the United Kingdom and the Republic of Ireland. In December 2011 Ameluz(®) obtained a centralized European approval as medicinal product for the first-line treatment of mild and moderate actinic keratosis in the face and on the scalp. The agreement with Spirit Healthcare will initially be valid until the end of 2016. Up to this time point Spirit Healthcare will exclusively market Ameluz(®) in the UK and Ireland. Thereafter the financial conditions will be reviewed. In return for exclusive marketing rights Spirit Healthcare will dedicate significant sales resource, partly funded by Biofrontera.  In addition Spirit Healthcare will receive 20% of the revenues obtained from Ameluz(®) in the UK and Ireland.  Biofrontera will take responsibility for scientific support, the logistics and all necessary approvals. A UK launch is anticipated in late 2012. The agreement with Spirit Healthcare allows Biofrontera a stronger strategic sales and marketing capability in the UK and Ireland than a normal license contract, without the risks of building a sales force and introducing a drug to the market. Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen ISIN: DE0006046113 WKN: 604611 Contact: Anke zur Mühlen Biofrontera AG Tel.: +49 (0214) 87 63 20, Fax.: +49 (0214) 87 63 290 E-mail: This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Biofrontera AG via Thomson Reuters ONE [HUG#1628959]